E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronica Lymphocytic Leukaemia (CLL) |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The principal objective of the UKCLL07 study is to assess the efficacy and safety of subcutaneous alemtuzumab (MabCampath) in B-CLL patients with low levels of minimal residual disease. The UKCLL07 study aims to achieve the following primary research objectives: • Determine the rate of achieving MRD negativity as determined by 4 colour flow cytometry in patients with low levels of MRD following conventional therapy or who relapse at an MRD level after a previous MRD negative remission. • Assess the safety of alemtuzumab in the MRD positive setting.
|
|
E.2.2 | Secondary objectives of the trial |
The UKCLL07 study aims to achieve the following secondary research objectives: • Determine the clinical response to alemtuzumab therapy (by NCI Criteria). • Evaluate the time to MRD relapse. • Evaluate the overall survival. • Investigate the pharmacokinetic profile of alemtuzumab in the MRD setting. The study also contains a monitoring investigation whereby the patients disease status will be monitored on a 3 monthly basis but the patient will not receive any treatment at this time. The principal objective of this investigation is to observe the longer term effects of repeated alemtuzumab therapy on remission from minimal residual disease.
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
The following are necessary for entry: • At least 18 years old. • Be capable of giving written informed consent. • Previous confirmation of B-CLL with a characteristic immunophenotype on peripheral blood flow cytometry. • Creatinine and bilirubin <2 x upper limit of normal unless secondary to direct infiltration of the liver by CLL or haemolysis. • Patients must have achieved a complete remission or partial remission after previous therapy for CLL (as defined by NCI criteria). • Peripheral B-cell count should be less than 5 x 109/l. • At least 6 months since completing last therapy for CLL. • Have detectable MRD (MRD positive), as shown by peripheral blood or bone marrow involvement or have attained undetectable CLL (MRD negative remission). The latter group is eligible for registration and 3 monthly monitoring for MRD relapse.
|
|
E.4 | Principal exclusion criteria |
Patients who meet any of the following criteria will be excluded: • Lymph nodes of 2cm or greater in maximum diameter. • Peripheral B-CLL count greater than 5 x 109/l. Patients must not have progressed clinically (peripheral B-CLL count should be less than 5 x 109/l.) • HIV positive. • Patient has active or prior Hepatitis B or C • Active infection. • Past history of anaphylaxis following exposure to rat or mouse derived CDR-grafted humanised monoclonal antibodies. • Use of prior investigational agents within 6 weeks. • Pregnancy, lactation or women of child-bearing potential unwilling to use medically approved contraception whilst receiving treatment. • Men whose partners are capable of having children but who are not willing to use appropriate medically approved contraception during the study, unless they are surgically sterile. • CNS involvement with CLL. Mantle cell lymphoma. • Other severe, concurrent diseases or mental disorders. • Active secondary malignancy. • Persisting severe pancytopenia due to previous therapy rather than disease (neutrophils <0.5 x 109/l or platelets <50 x 109/l). • Patients previously treated with allogeneic SCT. • Patients who previously failed alemtuzumab therapy.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoints for the UKCLL07 study are as follows: • Proportion of patients with undetectable minimal residual disease at the end of alemtuzumab therapy. • Proportion of patients suffering an unacceptable level of toxicity.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as the date of the last visit of the last patient receiving the protocol based drug therapy. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |